Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: A RYTHMIC study.
Thierry J Molina, Maria V Bluthgen, Lara Chalabreysse...
https://pubmed.ncbi.nlm.nih.gov/33316754/Actively Recruiting
Led by Erasmus Medical Center · Updated on 2024-03-27
1020
Participants Needed
1
Research Sites
N/A
Total Duration
Thymic epithelial tumors are uncommon growths in the front part of the chest, with surgery as the main treatment. Post-surgery radiotherapy is often used for more extensive or aggressive tumors based on the WHO classification, which divides tumors into types A, AB, B1, B2, B3, and thymic carcinoma. However, this classification can vary between pathologists and does not always predict the chance of the tumor returning accurately. Researchers are developing artificial intelligence AI models to improve how these tumors are classified and to better predict the risk of recurrence. This international project uses three existing databases from Rotterdam, Maastricht, and Lyon. One database is used to build the AI models, while the other two are used to test and validate them. The study aims to create AI tools that help pathologists correctly identify tumor subtypes and guide treatment decisions, especially about the need for additional radiotherapy. Participants include patients with different thymic epithelial tumor subtypes and those who have experienced tumor recurrence. The study involves analyzing digital pathology images and clinical information using AI diagnostics and recurrence prediction tools. Researchers will measure progress by working with the databases and developing deep learning models for classification and recurrence prediction over several months. The project supports better treatment planning by providing more accurate tumor subtyping and risk assessment.
CONDITIONS
Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors
A
Anna Salut Esteve Domínguez
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Erasmus Medical Center
Lead Sponsor
Maastro Clinic, The Netherlands
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 32 months
Participants undergo advanced histological image analysis using Artificial Intelligence to classify thymic epithelial tumors and predict recurrence risk.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Thierry J Molina, Maria V Bluthgen, Lara Chalabreysse...
https://pubmed.ncbi.nlm.nih.gov/33316754/Janina L Wolf, Francien van Nederveen, Hans Blaauwgeers...
https://pubmed.ncbi.nlm.nih.gov/32506527/Erasmus Medical Center
Lead Sponsor
Maastro Clinic, The Netherlands
Collaborating Sponsor